MSH2 and cervical cancer: MMR-D is also suggested as a prognostic marker in colorectal cancer, where MMR-D predicts favorable disease outcome.9 In endometrial cancer, no significant difference in survival for MMR-D and MMR-proficient (MMR-P) tumors is reported,10 but high levels of MSH-6 independently predict poor survival.11 For MSH-2, high expression is related to poor outcome in oral squamous carcinoma.12 The prognostic impact of differential MMR expression has, to our knowledge, not previously been explored in cervical cancer.